+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

North America Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country

  • PDF Icon

    Report

  • 117 Pages
  • June 2020
  • Region: North America
  • The Insight Partners
  • ID: 5116932
UP TO OFF until Jun 30th 2024
The North America antibiotics market is expected to reach US$ 18,004.25 million by 2027 from US$ 13,527.79 million in 2019. The market is estimated to grow with a CAGR of 3.9% from 2020 to 2027.

The antibiotics market is growing primarily due to prevalence of infectious diseases and increasing development of generic drugs in the North America region. Restraining factors, such as tedious and expensive process of antibiotic development is likely to slow down the growth of the market in the coming years. Additionally, growing investments to combat antimicrobial resistance and incorporation of novel computing technologies for antibiotics discovery are likely to increase the growth of the Antibiotics market in the forecast period.

Antibiotics refer to a class of medicines containing substances that are active against bacteria. These medicines either kill the bacteria or control the infection by inhibiting the bacterial reproduction, which in turn helps patient to recover. Antibiotics are specific to the type of bacteria being treated and are not able to be interchanged from one infection to another.

The prevalence of infectious disease, especially caused by bacteria is increasing day by day. According to a study published by the American Society for Microbiology (ASM) in 2019, Carbapenem-resistant bacterial infections risk factor leads to ~49,000 hospitalization cases in the US each year. Moreover, according to CDC, in 2018, there were around 49,157 pneumonia deaths, which accounted for 15:1 per 100,00 people; moreover, in the United States, an estimated 48 million foodborne diarrhea illnesses occur annually, resulting in more than 128,000 hospitalizations and 3,000 deaths. According to CDC, campylobacter causes an estimated 1.5 million illnesses each year in the United States. Thus, the increasing prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period. The prevalence of antimicrobial resistant bacteria is also increasing in developing and developed countries. Thus, the increasing prevalence of such drug-resistant bacteria compels the manufacturers and R&D faculties to come up with new effective variants of antimicrobials against the new and old bacterial strains, thereby fueling the growth of the antibiotics market.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak. This has eventually shifted their focus from development of new antibiotics to vaccine development for COVID-19. Moreover, diversion of resources from antibiotics development to coronavirus treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, pharmaceutical supplies and procurement are also badly affected by the outbreak of COVID-19 in North America.

In 2019, the cephalosporin segment accounted for the largest share of the market; it is further expected to continue its dominance during the forecast period. This class of antibiotics is usually safe due to low toxicity to self-cells and remarkable efficiency against susceptible bacteria. On the other hand, fluoroquinolones are expected to register the highest CAGR in the antibiotics market during 2020-2027.

Some of the significant secondary sources for Antibiotics market included in the report are the World Health Organization (WHO), Food and Drug Administration (FDA), American Society for Microbiology (ASM), Centers for Disease Control and Prevention (CDC), Center for Disease Dynamics, Economics & Policy (CDDEP), and others.

Reasons to Buy:
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Antibiotics Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America Antibiotics Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Antibiotics Market - By Drug Class
1.3.2 North America Antibiotics Market - By Action Mechanism
1.3.3 North America Antibiotics Market - By Country
2. North America Antibiotics Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Antibiotics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Antibiotics Market - North America PEST Analysis
4.3 Expert Opinion
5. North America Antibiotics Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Bacterial Infections
5.1.2 Increasing Development of Generic Drugs
5.2 Key Market Restraints
5.2.1 Tedious and Expensive Process of Antibiotic Development
5.3 Market Opportunities
5.3.1 Growing Investments to Combat Antimicrobial Resistance
5.4 Future Trends
5.4.1 Incorporation of Novel Computing Technologies for Antibiotics Discovery
5.5 Impact analysis
6. Antibiotics Market - North America Analysis
6.1 North America Antibiotics Market Revenue Forecasts and Analysis
7. North America Antibiotics Market Analysis And Forecasts To 2027 - By Drug Class
7.1 Overview
7.2 North America Antibiotics market, By Drug Class 2019 & 2027 (%)
7.2.1 North America Antibiotics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
7.3 Sulfonamides
7.3.1 Overview
7.3.2 North America Sulfonamides Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Aminoglycosides
7.4.1 Overview
7.4.2 North America Aminoglycosides Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Carbapenem
7.5.1 Overview
7.5.2 North America Carbapenem Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Macrolides
7.6.1 Overview
7.6.2 North America Macrolides Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Fluoroquinolones
7.7.1 Overview
7.7.2 North America Fluoroquinolones Market Revenue and Forecasts to 2027 (US$ Mn)
7.8 Penicillin
7.8.1 Overview
7.8.2 North America Penicillin Market Revenue and Forecasts to 2027 (US$ Mn)
7.9 Cephalosporins
7.9.1 Overview
7.9.2 North America Cephalosporins Market Revenue and Forecasts to 2027 (US$ Mn)
7.10 Others
7.10.1 Overview
7.10.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. North America Antibiotics Market Analysis - By Action Mechanism
8.1 Overview
8.2 North America Antibiotics Market, By Action Mechanism 2019-2027 (%)
8.2.1 North America Antibiotics Market Revenue and Forecasts to 2027, By Action Mechanism (US$ Mn)
8.3 Mycolic Acid Inhibitors
8.3.1 Overview
8.3.2 North America Mycolic Acid Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 RNA Synthesis Inhibitors
8.4.1 Overview
8.4.2 North America RNA Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 DNA Synthesis Inhibitors
8.5.1 Overview
8.5.2 North America DNA Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Protein Synthesis Inhibitors
8.6.1 Overview
8.6.2 North America Protein Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Cell Wall Synthesis Inhibitors
8.7.1 Overview
8.7.2 North America Cell Wall Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Antibiotics Market Revenue and Forecasts To 2027 - Geographical Analysis
9.1 North America Antibiotics Market Revenue and Forecasts To 2027
9.1.1 Overview
9.1.2 North America: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.3 North America: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.4 North America: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.5 North America: Antibiotics Market, by Country, 2019 & 2027 (%)
9.1.6 US: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.1 US: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.2 US: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.6.3 US: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.7 Canada: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.1 Canada: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.2 Canada: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.7.3 Canada: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.8 Mexico: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.1 Mexico: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.2 Mexico: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.8.3 Mexico: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
10. Impact of COVID-19 Pandemic on North America Antibiotics Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
11. Company Profiles
11.1 Pfizer Inc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Johnson & Johnson Services, Inc.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Eli Lilly and Company.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Word Index

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Johnson & Johnson Services, Inc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company.
  • Abbott
  • Pfizer Inc